Title: Clinical study on MMED regimens for relapsed or refractory patients with acute lymphocyte leukemia and non-Hodgkin lymphoma origin from B lymphocyte
Abstract: Objective:To study the clinical effect and safety of MMED chemotherapy regimen for relapsed or refractory patients with acute lymphocyte leukemia and non-Hodgkin lymphoma origin from B lymphocyte.Methods:Between 2004 to 2006,ten patients with relapsed or refractory acute B lymphocyte leukemia and sixteen patients with non-Hodgkin lymphoma(B lymphocyte type) received MMED regimen(mitoxantrone 6mg/d d1~3 iv drip,methotrexate 100mg/d d1,d8 iv drip,etoposide 100mg/d d1~5 iv drip,dexmethasone d1~8 iv drip).Results:The complete response rate of acute lymphocyte leukemia was 30.0%;the overall response rare was 80.0%.The complete response rate of non-Hodgkin lymphoma was 37.5%;the overall response rare was 87.5%.Myelosuppression was observed in all patients,non hematological toxicity was mild,and no ulcer developted in oral member.Conclusion:MMED regimen is effective and well tolerated for patients with acute lymphocyte leukemia and non-Hodgkin lymphoma origin from B lymphocyte.
Publication Year: 2007
Publication Date: 2007-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot